 The FDA has accepted for review BeiGene Ltds NASDAQ: BGNE supplemental marketing application for Brukinsa zanubrutinib for marginal zone lymphoma MZL and granted priority review. The application covers adult MZL patients who have received at least one prior anti-CD20-based therapy. 